Sinus node if channel inhibition - A new therapeutic approach to heart rate lowering

Current Drug Therapy

Volumn 4, Issue 1, 2009, Pages 12-18

  Scott, Anne E ^a,b   Kruszweski, Kirsten ^a,b   Leslie, Stephen J ^b,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b RAIGMORE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

Author keywords

Chronic stable angina; Funny channel; Heart rate lowering; Ivabradine

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; IVABRADINE; LANSOPRAZOLE; NITRATE; OMEPRAZOLE; PLACEBO; PROPRANOLOL; ZATEBRADINE;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE TOLERANCE; FLUSHING; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE POTENTIAL; HEART MUSCLE REVASCULARIZATION; HEART RATE; HEART REPOLARIZATION; HUMAN; HYPOTENSION; INOTROPISM; LETHARGY; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINUS NODE; SLEEP DISORDER; STABLE ANGINA PECTORIS; TACHYCARDIA; UNSTABLE ANGINA PECTORIS; VISUAL DISORDER;

EID: 65349153163     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488509787081859     Document Type: Review

References (44)

1. Allender S, Peto V, Scarborough P, Boxer A, Rayner M. Coronary heart disease statistics. London: British Heart Foundation 2006.
2. Task Force of the European Society of Cardiology. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18: 394-413.
3. Yusuf S, Petro R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
4. CIBIS -II investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353: 9-13.
5. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). J Am Med Assoc 2000; 283: 1295-302.
6. Kristal-Boneh E, Silber H, Harari G, et al. The association of resting heart rate with cardiovascular, cancer and all-cause mortality: eight-year follow-up of 3527 male Israeli employees (the CORDIS study). Eur Heart J 2000; 21: 116-24.
7. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J 2003; 125: 1148-54.
8. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999; 1(Suppl. H): H64-9.
9. Chang M, Havlik RJ, Corti MC, et al. Relation of heart rate at rest and mortality in the Womaen's Health and Aging Study. Am J Cardiol 2003; 92: 1294-9.
10. Von Arnim T. Medical treatment to reduce ischemic burden: Total Ischaemic Burden Bisoprolol Study (TIBBS), a mulitcenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol 1995; 25: 231-8.
11. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. J Am Med Assoc 1988; 260(15): 2259-63.
12. AMSA study group (Amlodipine Metoprolol Stable Angina). Amlodipine versus slow release metoprolol in the treatment of stable exertional angina pectoris (AMSA). Scand Cardiovasc J 2000; 34: 475-9.
13. Chugh SK, Digpal K, Hutchinson T, McDonald CJ, Miller AJ, Lahiri A. A randomized, double-blind comparison of the efficacy and tolerability of once daily modified release diltiazem capsule with once daily amlodipine tablets in patients with stable angina. J Cardiovasc Pharmacol 2001; 38: 356-64.
14. Multicentre Diltiazem Post Infarction Trial Research Group. The effects of diltiazem on mortality and reinfarction after myocardial infarction. N Eng J Med 1998; 319: 385-92.
15. Packer M, O'Connor CM, Ghali JK, et al. (1996) Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Amlodipine Survival Evaluation Study Group. N Eng J Med 1996; 335: 1107-14.
16. Thollon C, Bidouard JP, Cambarrat C, et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol 1997; 339: 43-51.
17. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004; 64: 1757-65.
18. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996; 118: 1051-7.
19. Bucchi A, Barbuti A, Baruscotti M, DiFrancesco D. Heart rate reduction via selective 'funny' channel blockers. Curr Opin Pharmacol 2007; 7: 208-13.
20. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and anti-ischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107: 817-23.
21. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-36.
22. Francois-Bouchard M, Simonin G, Bossant MJ, Boursier-Neyret C. Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromat B 2000; 745: 261-9.
23. Klippert P, Jeanniot JP, Polve S, Lefevre C, Merdjan H. Determination of ivabradine and its N-demethylated metabolite in human plasma and urine, and in rat and dog plasma by a validated high-performance liquid chromatographic method with fluorescence detection. J Chromat B 1998; 719: 125-133.
24. Ragueneau I, Jochemsen R, Funck-Bretano C, Jaillon P. Pharmacokinetic-pharmacodynamic modelling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998; 64: 192-203.
25. Portoles A, Calvo A, Terleira A, et al. Lack of pharmacokinetic interaction between omeprazole or lansoprazole in healthy volunteers an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. J Clin Pharmacol 2006; 46(10): 1195-203.
26. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 1994; 112: 37-42.
27. Bucchi A, Barbuti A, Baruscotti M, DiFrancesco D. Heart rate reduction via selective 'funny' channel blockers. Curr Opin Pharmacol 2007; 7: 208-13.
28. Vilaine JP, idouard JP, Lesage L, Reure H, Peglion JL. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol 2003; 42: 688-96.
29. Monnet X, Ghaleh B, Colin P, de Curzon OP, Giudicelli JF, Berdeaux A. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther 2001; 299: 1133-9.
30. Monnet X, Colin P, Ghaleh B, Hittinger L, Giudicelli JF, Berdeaux A. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J 2004; 25: 579-86.
31. Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 2004; 308: 236-40.
32. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003; 284: H676-82.
33. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109(13): 1674-9.
34. Mulder P, Thuillez C. Heart rate slowing for myocardial dysfunction heart failure. Adv Cardiol 2006; 43: 97-105.
35. Frishman WH, Pepine CJ, Weiss RJ, Baiker WM. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, doubleblind, placebo-controlled, parallel-group study. J Am Coll Cardiol 1995; 26: 305-12.
36. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomized, double-blind, multicentre, noninferiority trial. Drugs 2007; 67: 393-405.
37. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003; 100: 149-55.
38. Fox K, Ferrari R, Tendera M, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 2006; 152(5): 860-6.
39. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 (9641): 817-21.
40. Giannoglou GD, Chatzizisis YS, Zamboulis C, et al. Elevated heart rate and atherosclerosis: An overview of the pathogenic mechanisms. Int J Cardiol 2008; 126(3): 302-12.
41. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50(9): 823-30.
42. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.
43. Menown IB. Ivabradine: a new strategy for management of stable angina. Br J Hosp Med 2007; 68: 321-5.
44. Savelieva I, Camm AJ. I(f) Inhibition with Ivabradine: Electrophysiological Effects and Safety. Drug Safety 2008; 31: 95-107.